Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial) ; volume:11 ; number:1 ; day:4 ; month:8 ; year:2011 ; pages:1-11 ; date:12.2011
BMC cancer ; 11, Heft 1 (4.8.2011), 1-11, 12.2011
- Creator
-
Eckes, Jürgen
- Contributor
-
Schmah, Oliver
Siebers, Jan W.
Groh, Ursula
Zschiedrich, Stefan
Rautenberg, Beate
Hasenburg, Annette
Jansen, Martin
Hug, Martin J.
Winkler, Karl
Pütz, Gerhard
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-11-337
- URN
-
urn:nbn:de:1111-2016030364375
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Eckes, Jürgen
- Schmah, Oliver
- Siebers, Jan W.
- Groh, Ursula
- Zschiedrich, Stefan
- Rautenberg, Beate
- Hasenburg, Annette
- Jansen, Martin
- Hug, Martin J.
- Winkler, Karl
- Pütz, Gerhard
- SpringerLink (Online service)
Other Objects (12)
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer